

**Management Board's report on the resolutions submitted
to the Combined General Meeting of 10 May 2012**

* * *

RESOLUTIONS WITHIN THE FIELD OF COMPETENCE OF THE ORDINARY GENERAL MEETING

Approval of corporate financial statements for 2011 (1st Resolution)

The General Assembly is hereby requested to approve the transactions and annual financial statements of AREVA for the 2011 financial year which shows a net profit of €1,182,442,606.90.

Approval of consolidated financial statements for 2011 (2nd resolution)

The General Assembly is hereby requested to approve the consolidated financial statements of the AREVA Group for the 2011 financial year, as submitted in the Auditors' report, showing a consolidated net loss (group share) of €2,424,000,000.00.

Assignment of 2011 financial year results (3rd resolution)

The 3rd resolution focuses on the assignment of results.

Profits for the year	€1,182,442,606.90
Amount set aside for legal reserve (10% of share capital)	€412,503.30
Balance carried forward for the year	€2,652,618,376.27
Representing a distributable result (Art. L. 232-11 of the French Commercial Code) of	€3,834,648,479.87
Which is entirely assigned to the balance carried forward.	

Would the Assembly approve this proposal, no dividends would be paid to shareholders for the 2011 financial year.

Approval of agreements and commitments governed by the terms of Articles L225-86 and L225-90-1 of the French Commercial Code (4th to 9th resolutions)

Pursuant to Articles L.225-86 and L.225-90-1 of the French Commercial Code, the Management Board hereby proposes that you approve the regulated agreements and commitments described in the special report of the Auditors, and featured on page 359 of the AREVA 2011 Reference Document.

Setting of sitting fees for Supervisory Board members for the 2012 financial year (10th resolution)

The Management Board hereby proposes that you set the sitting fees allocated to members of the Supervisory Board for the 2011 financial year at €400,000, i.e. a 20% cut compared with the previous financial year.

Authorisation to be granted to the Management Board to trade the Company's shares (11th resolution)

The General Meeting held on 27 April 2011 authorised the Company to trade its own shares on the stock market. This authorisation has not been used and shall expire in October 2012. You are hereby requested to renew this authorisation to trade the Company's shares for the same 18-month period, thereby repealing the previous authorisation and under the following terms and conditions:

- Maximum buying price: €40 (excluding acquisition fees)
- Maximum ownership percentage: 10% of share capital
- Maximum number of shares available for acquisition: 38 320 485 shares
- Maximum face amount for buying of shares: €1,532,819,400

Buying of shares may help to set up programs for employees or company managers, stock option or share subscription or free share allocation plans, carry out financial transactions through transfers, assignments or share-for-share exchanges within the framework of external growth operations, and cover securities entitling the holder to Company shares, as well as to implement any practices acceptable on the market or that would become accepted by the market authorities, subject to notification of the Company's shareholders by means of a press release.

RESOLUTIONS WITHIN THE FIELD OF COMPETENCE OF THE EXTRAORDINARY GENERAL ASSEMBLY

Amendment of by-laws (12th resolution)

The 12th resolution proposes an amendment of Article 22 of the Company's by-laws with a view to improving the Company's governance.

The proposed amendments comprise:

- Setting up a Commission on the Supervisory Board known as the "Ethics Commission",
- Obtaining prior approval from the Supervisory Board for all decisions taken by the Management for amounts above €20 million and concerning investment projects and decisions to set up a new site or expand the capacity of an existing site, and make acquisitions or take out stakes in companies newly formed or to be formed.
- Expanding the missions of the Strategic and Investment Commission that would henceforth be responsible for reviewing the projects mentioned hereinabove.

Pursuant to Article 2 of the French Decree No. 83-1116 of 21 December 1983 regarding the "Société des Participations du Commissariat à l'Énergie Atomique" (AREVA), these amendments to the by-laws shall be approved by decree.

Delegation of financial authorities

The following table provides an overview of the financial authorisations you are hereby requested to grant to the Management Board.

Summary of purpose	Date of General Meeting granting authorisation	Period of authorisation	Maximum amount of authorisation in face value for capital increases and in principal for debt obligations
Delegation of authority to be granted to the Management Board to increase the capital by issuing shares, with preservation of pre-emptive rights for shareholders to subscribe ordinary shares or securities granting access to the Company's share capital (13 th resolution)	10 May 2012	26 months	Maximum amount of capital increases: €290 million (*) Maximum amount of debt obligations: €290 million (*)
Delegation of authority to the Management Board to increase the capital by issuing shares, with removal of pre-emptive rights for shareholders to subscribe ordinary shares or securities granting access to the Company's share capital by public offering (14 th resolution).	10 May 2012	26 months	Maximum amount of capital increases: €290 million (*) Maximum amount of debt obligations: €290 million (*)
Delegation of authority to be granted to the Management Board to increase capital by issuing ordinary shares or securities granting access to the share capital by private offering as provided for in Article L.411-2 II of the French Monetary and Financial Code, with removal of pre-emptive rights for shareholders (15 th resolution).	10 May 2012	26 months	Maximum amount of capital increases: €290 million (*) Maximum amount of debt obligations: €290 million (*)
Delegation of authority to be granted to the Management Board to increase the number of securities to be issued in case of a capital increase with or without pre-emptive rights for the shareholders (16 th resolution).	10 May 2012	26 months	15% of the initial issue (*)
Delegation of authority to be granted to the Management Board to increase the share capital by issuing ordinary shares with a view to paying for contributions in kind made to the Company and comprising equity securities or securities granting access to share capital (18th resolution).	10 May 2012	26 months	10% of share capital (*)
Delegation of authority to be granted to the Management Board to increase share capital by incorporating reserves, profits or premiums (19th resolution).	10 May 2012	26 months	Total of amounts that can be incorporated
Delegation of authority to the Management Board to increase share capital by issuing ordinary shares reserved for members of a corporate savings plan run by the Company or its Group (20th resolution).	10 May 2012	18 months	2% of share capital

(*) The overall nominal ceiling of capital increases, be the immediate or long-term, achievable by virtue of the authorities conferred on the Management Board by the 13th, 14th, 15th, 16th and 18th resolutions shall be set at €290 million.

The delegations of authority mentioned in the 13th, 14th, 15th, 16th and 18th resolutions are meant to equip the Management Board with the necessary flexibility, where needed, to issue different securities provided for by the regulations in force, and to adjust them more effectively to market prospects and to the Company's needs.

The Management Board shall therefore be authorised to issue shares and securities granting access to share capital, or entitling the holder to debt obligations, in France or abroad, in euros or foreign currencies, preserving or removing pre-emptive rights for shareholders, depending on the prospects on financial markets and the Company's interests and those of its shareholders.

Additionally, it may be decided, when needed, to proceed with a private offering of securities to qualified investors or a closed circle of investors (15th resolution).

These delegations shall be applied in the issuance of equity securities and securities granting access to the share capital within the limits of a nominal ceiling of €290 million applied to the 16th, 17th and 18th resolutions.

In case of additional requests to subscribe to the capital increase, with or without removal of the pre-emptive rights mentioned in the 13th, 14th and 15th resolutions, the 16th resolution provides that the number of securities may be increased as per the legal conditions and limits, namely within the limits of 15% of the initial issuance, and within 30 days from the closing of subscriptions and at the same price as the one retained for the said issuance. Additional share issuances by applying the greenshoe option (16th resolution) shall be charged to the nominal ceiling of €290 million.

Delegation of authority to be granted to the Management Board to increase share capital by issuing, while preserving the pre-emptive rights of the shareholders, ordinary shares or securities granting access to the Company's share capital (13th resolution)

The 13th resolution seeks to grant the Management Board the authority needed to issue, while maintaining the pre-emptive rights of the shareholders, Company shares or securities granting access, immediately or over the long term, to present or future shares, for a fee or free of charge, or entitling them to debt obligations.

In case of issuance of securities granting access over the long term to new shares (such as equity warrant bonds, convertible bonds, or detachable equity warrants), the General Assembly's decision shall entail a waiver by shareholders of their entitlement to subscribe to any shares that might be obtained from the securities issued initially. The General Assembly's authorisation shall equally offer the possibility to issue securities entitling the holder to shares already issued by the Company, such as bonds convertible into shares to be issued or exchangeable for existing shares.

This authorisation shall be granted for a maximum nominal amount of capital increases achievable immediately or in the long term by virtue of this delegation and issuance of securities entitling the holder to debt obligations worth €290 million, with the understanding that the said amount would be charged to the overall capital increase ceiling set out in the 21st resolution below.

The Management Board would be authorised to issue the shares in one or more batches, and, in accordance with the law, may grant excess subscription rights to shareholders. It may issue Company stock purchase warrants not only by subscription offers, but equally by

awarding bonus shares to holders of previously issued shares and, in each case, where the subscriptions fail to cover the entire issuance, decide, in the order it shall determine and in accordance with the law, to limit it to the amount of subscriptions received, or to partly or fully divide the unsubscribed shares or offer them to the public in France or abroad.

The Management Board may debit the capital increase charges from the premiums related thereto and deduct the necessary amounts from the said premiums to make up the legal reserve.

This delegation of authority would be granted for a period of 26 months effective from this General Meeting.

Delegation of authority to be granted to the Management Board to increase share capital by issuing, while removing the pre-emptive rights of the shareholders, ordinary shares or securities granting access to the Company's share capital by public offering (14th resolution)

The 14th resolution would delegate authority to the Management Board to conduct transactions by issuing, with removal of pre-emptive rights, in one or more batches, in France or abroad, shares and other securities granting access, immediately or in the future, to present or future shares within the limits of a nominal amount of €290 million, with the understanding that this amount would be charged to the maximum overall ceiling mentioned in the 21st resolution hereinafter, and in accordance with the same terms as those of the 13th resolution hereinabove.

It is stated that the issue price for shares issued shall be at least equivalent to the minimum amount authorised by the laws and regulations in force at the issuance date, i.e. the weighted average price of the last three trading sessions prior to the setting of the price, possibly minus a maximum discount of 5%.

The General Assembly's decision shall entail a waiver by shareholders of their entitlement to subscribe to any shares that might be obtained from the securities issued initially. However, pursuant to Article L.225-135 paragraph 5 of the French Commercial Code, the Management Board shall be authorised to grant shareholders a priority subscription period, which shall not give rise to any negotiable rights and should be exercised proportionately to the number of shares held by each shareholder.

This delegation of authority shall be granted for a period of 26 months effective from this General Meeting.

Delegation of authority to be granted to the Management Board to increase share capital by issuing ordinary shares or securities granting access to the Company's share capital, by means of private offering as mentioned in Article L.411-2 II of the French Monetary and Financial Code, with removal of the pre-emptive rights of the shareholders (15th resolution)

The 15th resolution would delegate authority to the Management Board to conduct transactions within the framework of an offer mentioned in Article L. 411-2 II of the French Monetary and Financial Code, i.e. by private offering to qualified investors or a closed circle of investors, within the maximum legal limit of 20% of the share capital per year, and whatever the case, within the limit of a nominal amount of €290 million. This delegation would be granted under the same terms and conditions as those in the 14th resolution

above. it would equally involve issuances, with removal of pre-emptive rights, conducted in one or more batches, of shares and other securities granting immediate or future access to present or future shares.

This delegation of authority shall be granted for 26 months effective from this General Assembly.

Delegation of authority to be granted to the Management Board to increase the number of securities to be issued in case of capital increase with or without pre-emptive rights for shareholders (16th resolution)

The 16 resolution would delegate authority to the Management Board to use the powers conferred by Article L.225-135-1 of the French Commercial Code in case of additional demand for the securities initially issued under the capital increase operations, with or without pre-emptive rights, decided following the 13th, 14th and 15th resolutions. This option consists in increasing the number of securities to be issued by issuing additional securities at the same price as the one retained for the initial offer, within the timeline and the limits set out by the regulations in force, i.e. within 30 days from the closing of the subscription period and limited to 15% of the initial issue, without exceeding the limit of the nominal amount set out by the 13th, 14th and 15th resolutions.

This delegation of authority would be granted for 26 months effective from this General Meeting.

Delegation of authority to be granted to the Management Board in case of issuance, with removal of pre-emptive rights, of shares or other securities granting immediate or long-term access to the Company's share capital, with a view to setting the issue price, within the limits of 10% of the Company's share capital, based on the terms and conditions retained by the General Assembly (17th resolution)

The 17th resolution would delegate authority to the Management Board to set the issue price within the framework of issuances without pre-emptive rights, conducted pursuant to the 14th and 15th resolutions, and limited to 10% of the Company's share capital yearly (including shares issued pursuant to the 16th resolution).

The price to be set by the Management Board would be at least equivalent to the average weighted share price on Euronext Paris for the last three trading sessions prior to the decision setting the price, possibly minus a maximum discount of 5%. Additionally, the issue price for shares granting access to share capital must be such that the amount received immediately by the Company, plus what it may subsequently receive, as the case may be, should, for each share issued under these securities issuance, be at least equivalent to the minimum subscription price set out hereinabove.

This delegation of authority would be granted for a period of 26 months effective from this General Meeting.

Delegation of authority to be granted to the Management Board to increase share capital by issuing ordinary shares with a view to paying for contributions in kind made to the Company, and comprising equity securities or securities granting access to share capital (18th resolution)

The 18th resolution seeks to delegate authority to the Management Board to issue shares and other securities granting access to share capital, with removal of pre-emptive rights, in one or more batches, immediately or in the future, and limited to 10% of the Company's share capital, with a view to paying for contributions made to the Company, and comprising equity securities or securities granting access to the share capital of other companies, and limited to a nominal amount of €290 million, with the understanding that the overall ceiling for the capital increase specified in the 21st resolution will be charged to the said nominal amount.

Prior to any issuance, this authorisation shall be subject to the involvement of shares auditor.

This delegation of authority would be granted for a period of 26 months effective from this General Meeting.

Delegation of authority to be given to the Management Board to increase share capital by incorporating reserves, profits or premiums (19th resolution)

The 19th resolution would delegate authority to the Management Board to conduct capital increases, in one or more phases, by incorporating reserves, premiums, profits or other amounts, the capitalisation of which shall be legally and statutorily acceptable.

This decision, which does not necessarily give rise to the issuance of new shares, must be made by the Extraordinary General Assembly, deliberating with the quorum and majority required for ordinary shareholders' meetings.

The maximum nominal amount for the capital increases that may be carried in this case would be equivalent to the total amounts that can be incorporated and shall add to the overall ceiling for capital increase set out in the 21st resolution.

For the award of bonus shares, the Management Board may decide that the rights forming fractional shares would be non-negotiable and that the related shares would be sold, and the amounts derived from the said sale be handed over to owners of the rights under the terms and conditions set out by the law.

This delegation of authority shall be granted for a period of 26 months effective from this General Meeting.

Delegation of authority to be given to the Management Board to increase share capital by issuing ordinary shares reserved for members of a corporate savings plan run by the Company or its Group (20th resolution)

It should be noted that pursuant to the terms of Article L.225-129-6 paragraph 1 of the French Commercial Code, for any decision to increase the share capital, the General Assembly must form an opinion on any draft resolution aimed at achieving a capital increase reserved for employees of the Company, and conducted pursuant to the terms and conditions of Articles L.3332-1 and following of the French Labour Code.

Consequently, the Management Board hereby submits to vote, the 20th resolution, requesting that the necessary authority be delegated to it for a maximum period of 18 months, to increase the Company's share capital by issuing the Company's ordinary shares exclusively to company managers, employees and former employees that are members of a corporate savings plan run by the Company, and where necessary, its subsidiaries in accordance with the requirements of the law.

The capital increases achievable pursuant to this resolution shall not exceed 2% of the nominal amount of the share capital.

The ordinary share price would be determined in accordance with the law, making reference to the average trading prices for ordinary shares over the last twenty trading sessions prior to the date the decision is made setting the subscription opening date.

The maximum discount set out pursuant to Articles L. 3332-19 and following of the French Labour Code referring to the average trading prices over the last twenty trading sessions shall not exceed 20% or 30%, depending on the period of unavailability of the subscribed securities. However, the Management Board would be authorised to remove or reduce the above-mentioned discount, should it deem it necessary, particularly to take into account the legal, accounting, tax and social security, etc. systems locally applicable.

The shareholder's pre-emptive rights would be withdrawn and passed on to the corporate savings plan members stated hereinabove.

This delegation of authority would be granted for a period of 18 months effective from this General Meeting.

Overall limitation of issuance authorisations (21st resolution).

The 21st resolution would limit the overall maximum nominal amount for the capital increases achievable pursuant to the delegations mentioned in the 13th, 14th, 15th, 16th and 18th resolutions, to € 290 million euros. This shall be an overall ceiling common to the said resolutions, plus the nominal amount of any additional shares to be issued subsequently, in case of any new financial transactions, to safeguard the rights of holders of securities with access to share capital.

Common provisions

The above-mentioned delegations of authority would be granted with right to subdelegate under the terms and conditions provided for by the law.

The 13th, 14th, 15th, 16th, 18th, 20th and 21st resolutions have each been reviewed in separate auditor's reports, which reports have been made available to the shareholders in accordance with the laws and regulations.

Pursuant to Article 22 of the Company's by-laws, the implementation by the Management Board of the above-mentioned resolutions would be subject to the prior approval by the Supervisor Board.

Additionally, the Management Board hereby underscores that, pursuant to Article 2 of the French Decree No. 83-1116 of 21 December 1983 regarding the "Société des participations

du Commissariat à l'Énergie Atomique" (AREVA)., any capital increases decided pursuant to these resolutions shall each be subject to joint approval by the French Minister of Industry and the French Minister of Economy.

When using these delegations of authority (excluding the one of the 21st resolution), in accordance with the law, the Management Board would draw up an additional report describing the final terms and conditions for each of the issuances retained. This report and the reports of the auditors would then be made available to you at the head office and presented to you at the next general meeting in accordance with the laws and regulations.

Powers to fulfil formalities (22nd resolution)

The 22nd resolution shall authorise any bearer of a copy or excerpt of the minutes of the General Meeting, where needed, to fulfil the public notice and deposit formalities inherent in the organisation of your General Meeting.

The Special auditor's reports, this report and other documents related thereto have been put at your disposal for your information at the head office, in accordance with the conditions and timeline required by the law.

The AREVA Management Board

APPENDIX
to the Management Board's report on the resolutions submitted
to the Combined General Meeting of 10 May 2012

* * *

Conduct of business since 1st January 2012

- Following the Fukushima disaster, AREVA submitted in September 2011 additional safety assessments of its nuclear facilities at the request of ASN and the European authorities. Following its analysis, ASN deemed through its report published in January 2012, that the facilities assessed present an adequate level of safety; it asked the operators to improve the robustness of certain functions to face extreme situations going beyond their existing safety margins.
- Following a press release which reported unsourced comments concerning UraMin acquisition, AREVA has wanted to remind that the audition by members of the Commission des Finances from the French National Assembly, to which this release referred to, was held behind closed door.
- AREVA announced the sale of its 20% stake in the company Sofradir.
- ATMEA received the final report and findings of the review of ATMEA1 reactor safety objectives and options by the French nuclear safety authority (ASN). The ASN gave a favourable opinion on the safety options of the ATMEA1 reactor.
- EDF and AREVA have reached an agreement on the principles of a long-term partnership to supply natural uranium over the 2014-2030 period, ensuring the security of supply and the competitiveness of the French nuclear fleet.
- During its meeting held on December 12, 2011, devoted in particular to the examination of the 2011 closing estimates, the AREVA Executive Board indicated that it expected to book a provision of 1.46 billion euros (2.025 billion US dollars) in the company's accounts for fiscal year 2011 for impairment of assets for the reporting entity UraMin, a mining company acquired by AREVA in 2007, which, given the provision booked in 2010 (426 million euros), brings the value of these assets on the AREVA balance sheet down to 410 million euros.
Given the size of these provisions, the Supervisory Board decided to make three of its members, meeting as an ad hoc committee, in charge of analyzing the terms of acquisition of this company, as well as the key decisions made in this reporting entity up to 2011 and, based on the outcome of these analyses, to recommend to it any appropriate measures in AREVA's interest.
This committee reported on its work during the Supervisory Board meeting held on February 14, 2012. In light of this report, the Supervisory Board found that the fairness and reliability of the financial statements of previous years were not in question. Nevertheless, considering the malfunctionings raised, the Board considers it appropriate to thoroughly review AREVA's governance in order to ensure that decisions concerning large acquisitions or investments be reviewed and validated in the future under conditions ensuring better legal and financial security and enabling a more transparent dialogue between management and the Supervisory Board.
It thus asked the Executive Board to recommend, at the next General Meeting of Shareholders, that the by-laws of the company be modified to make the Supervisory Board's prior approval of investments, stake acquisitions and acquisitions mandatory above a threshold of 20 million euros. It also decided to set up a business ethics committee within the Supervisory Board responsible for ensuring that rules of conduct are properly applied.
Moreover, it asked the Executive Board to finalize in the shortest possible timeframe the internal procedure applicable to the review and validation of the various projects and decisions creating a commitment, and the procedures for monitoring their execution.
In addition, it noted that the deliberations of the Executive Board, like those of the bodies or authorities having received delegation of authority from it, must be systematically documented in writing, and asked the Executive Board to ensure that this rule is thoroughly applied.
It asked the Executive Board to install a resources and reserves committee under its direct authority, responsible for validating each year the resource and reserve estimates appearing in the Reference Document, based on the work of the Reserves Department. This committee, which will involve one or more recognized external experts, shall specify the methods and schedule for updating resources and

reserves. Its work shall be reported on an annual basis to the Audit Committee. Reference to the installation and operation of this committee shall appear in the Reference Document published by AREVA.

Lastly, it asked the Executive Board to study the transformation of the legal form of the company into a limited liability company with a board of directors.

- AREVA has achieved major milestones for EPRTM construction projects in the UK signing new agreements at the Franco-British summit in Paris on February 17, 2012. AREVA signed an enhanced cooperation agreement with Rolls-Royce to extend global cooperation which covers the manufacture of components for new nuclear power plants and other nuclear projects in the United Kingdom and beyond. It follows a global agreement signed between the two companies in March 2011. Moreover, AREVA has signed with EDF a Memorandum of Understanding relating to the delivery of the nuclear steam supply system and all central instrumentation and control systems for the Hinkley Point C project and confirming the timeframe for completing the negotiation for the contract.
- The two German utilities E.ON and RWE npower, partners in the joint venture Horizon Nuclear Power (HNP), have announced that they are not pursuing their project to build a nuclear power plant on the Wylfa site in North Wales, UK.
The decision taken by E.ON and RWE is motivated by the impact of the German government's nuclear phase-out policy and by the economic and financial crisis. They are looking for buyers for the Horizon project and stress the project is a highly attractive one. This approach is supported by AREVA.
The AREVA group, together with its partners and network of UK suppliers, stands by the British government in total commitment to playing a part in the implementation of the UK's energy and environmental policy. The policy aims to secure the country's supply of electricity and combat climate change by developing nuclear and renewable energies in a complementary manner.
AREVA is already carrying out engineering studies and producing forgings for EDF Energy as part of the project to build the first two British EPR™ reactors, planned for the Hinkley Point site. AREVA is also in preliminary discussions with NuGen, the British nuclear utility owned by GDF SUEZ and IBERDROLA, with a view to the construction of two additional EPR™ reactors.
AREVA's EPR™ technology has received provisional certification by the British safety authorities after four years of design studies, under the Generic Design Assessment (GDA) process. As global partner of the nuclear industry in the UK, it is also engaged in engineering and service activities and technical assistance for the Sellafield site.
In the field of renewable energy, AREVA is in advanced discussions to participate in offshore wind farm development projects off the coast of Britain.
- As part of the call for tenders for offshore wind power in France, the French government has just awarded a contract to the consortium led by Iberdrola and EOLE-RES for the development of the Saint-Brieuc (Côtes-d'Armor) wind farm, which was the most competitive field with three different technologies proposed. AREVA will build 100 turbines of 5 MW each for this wind farm, which is scheduled to enter into operation between 2017 and 2019, and will generate enough electricity to power a town of around 650,000 inhabitants.
The selection of the AREVA M5000 wind turbine by Iberdrola and RES, two leading energy operators, of which Iberdrola is the leader in renewables, demonstrates their recognition of the experience AREVA has acquired over the past years. In the North Sea, AREVA started up the Alpha Ventus pilot wind farm in 2009 and, by the end of 2013, will have installed more than 120 wind turbines, thereby maintaining its leading position in the high-power turbines market. AREVA will create two plants at Le Havre, one to manufacture turbines and the other for blades.
This industrial base is ideally placed to supply the largest offshore wind power market in the world, the Channel and the North Sea. In total, AREVA's wind power activities will enable the creation of some 2,000 jobs, through an extensive network of partners and suppliers throughout France, mainly concentrated in Brittany. Furthermore, AREVA's partners have signed agreements with other French industrial players, including STX in Saint-Nazaire, to build the wind turbine foundations.
- AREVA Solar, an AREVA subsidiary, has been awarded a contract by the Indian group Reliance Power Limited to build a 250 megawatt (MW) concentrated solar power (CSP) installation in India, which will become the largest in all of Asia. The project will help advance India's goal of adding 20,000 MW of solar energy by 2022 and will result in the avoidance of approximately 557,000 tons of CO2 emissions per year compared to a similar sized coal-fired power plant.

Under the contract, AREVA will build two 125 MW CSP plants using its Compact Linear Fresnel Reflector (CLFR) technology and will provide construction management services for the project. The first phase of the project is under construction, with a target commercial operation date of May 2013. The solar power plants will be located in Rajasthan.

- AREVA and EDF have signed an agreement for the supply of fuel assemblies and related services for 2013 and 2014. The two groups have also decided to negotiate a medium to long-term framework agreement on the production of fuel elements that reinforce the strategic partnership between AREVA and EDF in the supply of nuclear fuel. The agreement signed and the one currently under negotiation provide AREVA with a clearer picture of its future production program. On these competitive markets, AREVA is now the leading manufacturer worldwide of nuclear fuels.
